Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2021 | What is behind cenobamate’s remarkable efficacy against focal-onset seizures?

Cenobamate is an investigational antiepileptic drug with a unique dual mechanism of action. Evaluations of cenobamate in two major randomized controlled trials (NCT01397968; NCT01866111) demonstrated its unmatched efficacy in patients with uncontrolled focal epilepsy, with more than 20% of patients achieving seizure freedom. Bernhard Steinhoff, MD, PhD, Kork Epilepsy Center, Kehl-Kork, Germany, explains how cenobamate works via reduction of persistent currents though voltage-gated sodium channels and positive allosteric modulation of GABAA receptors at the non-benzodiazepine binding site. Investigations into this therapy are ongoing. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Prof. Steinhoff reports the following disclosures:
Paid consultant/advisor/lecturer: Arvelle, B. Braun Melsungen, Desitin, Eisai, GW Pharmaceuticals, Neuraxpharm, UCB and Zogenix
Research support: Eisai, GW Pharmaceuticals, Precisis, SK Life Science, UCB, and Zogenix.

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.